DiaMedica Therapeutics Inc.
NASDAQ:DMACBiotechnology
-$0.01 today
- Market cap
- $463.49M
- Beta
- 1.00
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.65
Volume 0.21M
Average 0.19M
DMAC Other Non-current Assets
Long-term assets not reported separately.
DiaMedica Therapeutics Inc.NASDAQ: DMAC
Other Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Other non-current assets remains negative
Q1 FY2026 other non-current assets was $400K, compared with $0 a year earlier.
Context
- Other non-current assets amounted to 0.8% of total assets at the end of Q1 FY2026, up 0.8 pp from a year earlier.
- Other non-current assets increased in 1 of the last 3 fiscal years.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 400K USD
- Year-over-year change
- -69.4%
| Period | Period end | Other Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 400K | -69.4% |
| FY2024 | 2024-12-31 | 1.31M | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Other Non-current Assets vs competitors
How DMAC compares with its peers on the latest reported figures
- DMAC's Mar 2026 other non-current assets of $400K is the 5th highest of the 7 companies compared; the peer median is $3.65M.
- Other non-current assets amounts to 0.8% of total assets for DMAC, versus a peer median of 0.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $56.57M | +54.3% | +191.2% | 15.6% | |
| Jun 2026 | $25.83M | +12.4% | +29.7% | 2.2% | |
| Mar 2026 | $5.41M | +66.6% | +44.5% | 1.3% | |
BIOABioAge Labs, Inc. | Mar 2026 | $1.9M | +692.9% | +453.9% | 0.5% |
| Mar 2026 | $400K | — | — | 0.8% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding DMAC) | $3.65M | +60.4% | +117.9% | 0.9% | |
Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
Intrinsic Alpha fair value
Locked
Current Price
$8.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.